Legato Capital Management LLC Has $277,000 Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Legato Capital Management LLC lessened its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,395 shares of the company's stock after selling 15,890 shares during the period. Legato Capital Management LLC's holdings in Castle Biosciences were worth $277,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Algert Global LLC grew its position in shares of Castle Biosciences by 0.4% during the 3rd quarter. Algert Global LLC now owns 134,321 shares of the company's stock worth $3,831,000 after purchasing an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Castle Biosciences by 11.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock worth $158,000 after acquiring an additional 604 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of Castle Biosciences by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company's stock worth $220,000 after acquiring an additional 675 shares during the period. Assetmark Inc. lifted its holdings in shares of Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company's stock worth $149,000 after acquiring an additional 748 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its holdings in shares of Castle Biosciences by 3.6% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company's stock worth $690,000 after acquiring an additional 845 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.

Castle Biosciences Price Performance

NASDAQ:CSTL traded down $0.01 on Tuesday, hitting $27.31. The company had a trading volume of 98,479 shares, compared to its average volume of 447,710. The stock has a market capitalization of $764.95 million, a price-to-earnings ratio of 136.93 and a beta of 0.91. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $27.76 and a two-hundred day moving average of $29.20. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84.

Wall Street Analysts Forecast Growth

CSTL has been the subject of a number of recent analyst reports. Lake Street Capital upped their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Canaccord Genuity Group upped their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. KeyCorp upped their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Robert W. Baird upped their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Finally, Stephens reaffirmed an "overweight" rating and set a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $40.29.

Insider Activity at Castle Biosciences

In other news, insider Derek J. Maetzold sold 986 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.03, for a total transaction of $27,637.58. Following the completion of the sale, the insider now directly owns 80,818 shares in the company, valued at $2,265,328.54. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $29.14, for a total transaction of $229,244.38. Following the sale, the director now owns 1,425 shares of the company's stock, valued at approximately $41,524.50. This trade represents a 84.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,771 shares of company stock valued at $886,112 in the last quarter. Insiders own 7.20% of the company's stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.